Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a [...]

Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations2021-06-03T06:07:22+00:00

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile The amendment will include the testing of higher doses, resulting in an increase in the total study population to 70 patients. The changes were unanimously recommended by the Clinical Advisory Board.

BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile2021-06-03T06:07:07+00:00

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis

BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference2021-06-03T06:06:55+00:00

Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform Clinical trials in three additional indications for BL-8040 to be initiated in 2015 Development strategy presented today at BioLineRx investor meeting in New York

Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment2021-06-03T06:10:31+00:00

Biokine Announces Issuance of Mexican Patent

Biokine Therapeutics Announces Issuance of Mexican Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Announces Issuance of Mexican Patent2021-06-03T06:05:52+00:00

Biokine Announces Issuance of European Patent

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

Biokine Announces Issuance of European Patent2021-06-03T06:05:30+00:00

Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment . BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.

Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment2021-06-03T06:05:16+00:00

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL8040

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment  Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany 

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL80402021-06-03T06:04:22+00:00
Go to Top